Abstract
Vasopeptidase inhibition is a novel treatment approach in cardiovascular disease such as hypertension and heart failure. Since the inhibition of the angiotensin-converting enzyme (ACE) turned out to represent a very successful principle in the treatment of hypertension in numerous large scale clinical studies, their results encouraged attempts to inhibit other key enzymes in the regulation of vascular tone as well - such as the neutral endopeptidase (NEP). Similar to ACE, NEP is an endothelial cell surface metalloproteinase, which is involved in the degradation of several regulatory peptides including the natriuretic peptides and thus augments vasodilatation and natriuresis through increased levels of atrial natriuretic peptide (ANP). By simultaneous inhibition of the RAS and potentiation of the natriuretic peptide system, combined NEP/ACE inhibitors - the so called vasopeptidase inhibitors - reduce vasoconstriction and enhance vasodilatation, therefore, decreasing peripheral vascular resistance and blood pressure. Based on these considerations, numerous preclinicial studies with vasopeptidase inhibitors were performed and revealed promising results in experimental hypertension. Correspondingly, large scale clinical studies in patients with hypertension are on the way. Their preliminary results indicate that combined inhibition of ACE and NEP by vasopeptidase inhibitors represents an effective strategy in the treatment of hypertension and other cardiovascular disease such as heart failure. However, clinical data also suggest that the incidence of angioedema may increase on vasopeptidase inhibition. Therefore, careful evaluation of the safety of this promising therapeutic principle in large scale clinical studies is mandatory before vasopeptidase inhibition may be considered a novel option in the treatment of cardiovascular disease.
Keywords: angiotensin, bradykinin, endothelin, endothelium, hypertension, nitric oxide
Current Pharmaceutical Design
Title: Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Volume: 11 Issue: 25
Author(s): T. Quaschning
Affiliation:
Keywords: angiotensin, bradykinin, endothelin, endothelium, hypertension, nitric oxide
Abstract: Vasopeptidase inhibition is a novel treatment approach in cardiovascular disease such as hypertension and heart failure. Since the inhibition of the angiotensin-converting enzyme (ACE) turned out to represent a very successful principle in the treatment of hypertension in numerous large scale clinical studies, their results encouraged attempts to inhibit other key enzymes in the regulation of vascular tone as well - such as the neutral endopeptidase (NEP). Similar to ACE, NEP is an endothelial cell surface metalloproteinase, which is involved in the degradation of several regulatory peptides including the natriuretic peptides and thus augments vasodilatation and natriuresis through increased levels of atrial natriuretic peptide (ANP). By simultaneous inhibition of the RAS and potentiation of the natriuretic peptide system, combined NEP/ACE inhibitors - the so called vasopeptidase inhibitors - reduce vasoconstriction and enhance vasodilatation, therefore, decreasing peripheral vascular resistance and blood pressure. Based on these considerations, numerous preclinicial studies with vasopeptidase inhibitors were performed and revealed promising results in experimental hypertension. Correspondingly, large scale clinical studies in patients with hypertension are on the way. Their preliminary results indicate that combined inhibition of ACE and NEP by vasopeptidase inhibitors represents an effective strategy in the treatment of hypertension and other cardiovascular disease such as heart failure. However, clinical data also suggest that the incidence of angioedema may increase on vasopeptidase inhibition. Therefore, careful evaluation of the safety of this promising therapeutic principle in large scale clinical studies is mandatory before vasopeptidase inhibition may be considered a novel option in the treatment of cardiovascular disease.
Export Options
About this article
Cite this article as:
Quaschning T., Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience, Current Pharmaceutical Design 2005; 11 (25) . https://dx.doi.org/10.2174/138161205774424708
DOI https://dx.doi.org/10.2174/138161205774424708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Current Knowledge of the Complement System and the Therapeutic Opportunities in Inflammatory Arthritis
Current Medicinal Chemistry Mast Cell Disorders In Drug Hypersensitivity
Current Pharmaceutical Design Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach
Current Vascular Pharmacology Genetic Engineering of Allergens for Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Metal Allergens of Growing Significance: Epidemiology, Immunotoxicology, Strategies for Testing and Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Renin-angiotensin System Blockade at the Level of the Angiotensin Converting Enzyme or the Angiotensin Type-1 Receptor: Similarities and Differences
Current Topics in Medicinal Chemistry Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews The Role of Immunosuppressive Medications in the Pathogenesis of Hypertension and Efficacy and Safety of Antihypertensive Agents in Kidney Transplant Recipients
Current Medicinal Chemistry Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Fixed Drug Eruption Due to Selective Hypersensitivity to Naproxen with Tolerance to other Propionic Acid NSAIDs
Recent Patents on Inflammation & Allergy Drug Discovery Naproxen: An Update on Physicochemical, Analytical and Pharmacological Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Reporting Rates of Yellow Fever Vaccine 17D or 17DD-Associated Serious Adverse Events in Pharmacovigilance Data Bases: Systematic Review
Current Drug Safety Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
Current Drug Metabolism The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews